Literature DB >> 9892184

Migration of human dendritic cells after injection in patients with metastatic malignancies.

M A Morse1, R E Coleman, G Akabani, N Niehaus, D Coleman, H K Lyerly.   

Abstract

Present clinical studies of active immunotherapy for malignancies using dendritic cells (DCs) require elucidation of the sites where DCs localize after injection. We evaluated the pattern of distribution of in vitro-generated, antigen-loaded, human DCs labeled with indium-111 oxyquinoline after i.v., s.c., and intradermal injection. Whereas the DCs injected i.v. localized in the lungs and then redistributed to the liver, spleen, and bone marrow, they were not detected in lymph nodes or tumors. A small percentage of DCs injected intradermally migrated rapidly to the regional lymphatics in some individuals. No lymph node activity was detected after s.c. injection. Our results demonstrate that DC distribution to sites of lymphoid tissue is dramatically affected by the mode of administration.

Entities:  

Mesh:

Year:  1999        PMID: 9892184

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

Review 1.  Active immunization of humans with dendritic cells.

Authors:  M V Dhodapkar; N Bhardwaj
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  Antitumor activities of human dendritic cells derived from peripheral and cord blood.

Authors:  Jin-Kun Zhang; Jun Li; Hai-Bin Chen; Jin-Lun Sun; Yao-Juan Qu; Juan-Juan Lu
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

3.  A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.

Authors:  Yefei Rong; Xia Qin; Dayong Jin; Wenhui Lou; Lili Wu; Dansong Wang; Wenchuan Wu; Xiaolin Ni; Zhengfa Mao; Tiantao Kuang; Ying Qin Zang; Xinyu Qin
Journal:  Clin Exp Med       Date:  2011-09-20       Impact factor: 3.984

4.  In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy.

Authors:  Nela Klein Gonzalez; Kerstin Wennhold; Sandra Balkow; Eisei Kondo; Birgit Bölck; Tanja Weber; Maria Garcia-Marquez; Stephan Grabbe; Wilhelm Bloch; Michael von Bergwelt-Baildon; Alexander Shimabukuro-Vornhagen
Journal:  Oncoimmunology       Date:  2015-06-17       Impact factor: 8.110

5.  Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells.

Authors:  J Zhang; J K Zhang; S H Zhuo; H B Chen
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 6.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 7.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA.

Authors:  Nada M Melhem; Sherrianne M Gleason; Xiang Dong Liu; Simon M Barratt-Boyes
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

9.  Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Authors:  Norimasa Matsushita; Hiroshi Komine; Annabelle Grolleau-Julius; Shari Pilon-Thomas; James J Mulé
Journal:  Cancer Immunol Immunother       Date:  2010-01-08       Impact factor: 6.968

Review 10.  Generation of dendritic cell-based vaccines for cancer therapy.

Authors:  G Reinhard; A Märten; S M Kiske; F Feil; T Bieber; I G H Schmidt-Wolf
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.